Delving into the Latest Updates on 浙江亚克药业有限公司 with Synapse

概览

疾病领域	数量

肿瘤	1

排名前五的药物类型	数量

中药	1

关联

1

项与浙江亚克药业有限公司相关的药物

20(S)-protopanoxadiol

20(S)-原人参二醇

靶点-

作用机制-

在研机构

浙江亚克药业有限公司 [+2]

原研机构

上海凯宝药业股份有限公司 [+2]

在研适应症

抑郁症 [+1]

非在研适应症-

最高研发阶段临床2期

首次获批国家/地区-

首次获批日期-

2

项与浙江亚克药业有限公司相关的临床试验

CTR20200340 / Not yet recruiting临床2期

探索益今生胶囊用于肺癌术后辅助化疗后疲劳 (气虚证)的有效性和安全性的随机双盲安慰剂对照多中心Ⅱa 期临床试验

(1) 探索益今生胶囊用于肺癌术后辅助化疗后疲劳(气虚证)的有效性； (2) 初步观察益今生胶囊临床使用的安全性。

开始日期-

申办/合作机构

浙江亚克药业有限公司

[+1]

CTR20130681 / Completed临床1期

益今生胶囊用于常规治疗结束后病情稳定的晚期实体瘤患者的耐受性和药代动力学I期临床研究

（1）主要目的：通过剂量递增试验，观察本品用于常规治疗结束后病情稳定的晚期实体瘤患者的耐受性及安全性，为II期临床试验推荐安全剂量。（2）次要目的：评价本品药代动力学特征和量效关系（PK/PD）。

开始日期2012-02-14

申办/合作机构

浙江亚克药业有限公司

[+1]

100 项与浙江亚克药业有限公司相关的临床结果

登录后查看更多信息

0 项与浙江亚克药业有限公司相关的专利（医药）

登录后查看更多信息

1

项与浙江亚克药业有限公司相关的文献（医药）

Zhongguo Yaoshi (Wuhan, China)

Pharmacokinetics of Murraya exotica L. leaves flavonoids and inclusion compound in rats

作者: Zheng, Bo ; Li, Jun ; Zhang, Jianfang

An HPLC method was established for the determination of Murraya exotica L. leaves flavonoids (JK) in plasma, and the pharmacokinetics of JK as well as the hydroxypropyl-β-cyclodextrin inclusion complex (JK-HP-β-CD) in rats was investigated.Rats received 200 mg·kg^-1 of JK and JK-HP-β-CD by oral administration.Blood samples were collected at different times.The concentrations of 5,7,3',4'-tetramethoxyflavone (JA) and 5,7,3',4',5'-pentamethoxyflavone (JB) in plasma were determined, which were the major components of JK.The DAS2.1.1 software was used to calculate the pharmacokinetic parameters.The concentration-time relationships of JK and JK-HP-B-CD were perfectly fitted to two-compartment model.The bioavailability of JA in the inclusion complex was 5.30 times as that in the free drug.The C_max of JA in inclusion complex was 3.42 times as that in the free drug.The bioavailability of JB in inclusion complex was 4.96 times as that in the free drug.The C_max of JB in inclusion complex was 2.93 times as that in the free drug.Compared with free drug, the bioavailability of inclusion complex was significantly improved.

100 项与浙江亚克药业有限公司相关的药物交易

登录后查看更多信息

100 项与浙江亚克药业有限公司相关的转化医学

登录后查看更多信息